Category: Pharma News

Pharmacopoeia standards for medications used in Ayurveda, Siddha, Unani, and homoeopathy will shortly be developed by PCIM&H.

The Pharmacopoeia Commission of Indian Medicine and Homoeopathy (PCIM&H) may soon start developing pharmacopoeia standards for the Ayurvedic, Siddha, Unani, and Homoeopathic medications under the “One Herb One Standard” (OHOS) among other projects during the budget year 2023–2024. According to…

Cabaletta Bio’s IND application for CABA-201 to treat systemic lupus erythematosus has been approved by the US FDA.

The US Food and Drug Administration has approved the company’s investigational new drug (IND) application for CABA-201, a fully human CD19-CAR T cell investigational therapy that contains the 4-1BB protein, according to Cabaletta Bio, Inc., a clinical-stage biotechnology company focused…

The Delhi High Court rejects Boehringer Ingelheim’s request for a temporary restraining order, and generic linagliptin production is permitted.

In a patent dispute involving the former’s diabetes drug linagliptin, a single judge of the Delhi High Court declined to grant an interim injunction in favour of German pharmaceutical giant Boehringer Ingelheim against Indian generic manufacturers, noting that the patent…

The FDA has fully approved Keytruda, a Merck anti-PD-1 medication, for use in a small number of adult and paediatric patients with advanced MSI-H or mismatch repair deficient solid tumours.

The US Food and Drug Administration (FDA) has fully approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of adult and paediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by an…

Back to top
WhatsApp Join Telegram